ESMO TAT 2023 | Advances in the role of ICIs in metastatic CRPC

Pasquale Rescigno, MD, PhD, Newcastle University, Newcastle, UK, discusses updates in the use of immune checkpoint inhibitors (ICIs) in metastatic castration-resistant prostate cancer (mCRPC). Whilst hormone therapies such as enzalutamide have improved outcomes in patients with mCRPC, immunotherapy has been less effective. However, ongoing trials have demonstrated promising results in patients with mismatch repair deficient mCRPC, and myeloid derived suppressor cells (MDSCs) have additionally be found to be a potential target. Dr Rescigno also talks on the connection between the gut microbiome and prostate cancer. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.